Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proteomic Analysis of Urinary Extracellular Vesicles for the Diagnosis of Prostate Cancer

By LabMedica International staff writers
Posted on 30 Apr 2020
A new method for diagnosis of prostate cancer relies on advanced proteomics-based analysis of extracellular vesicles isolated from urine samples.

Extracellular vesicles (EVs) are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. More...
The vesicles, which contain RNA, proteins, lipids, and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies (MVBs) fuse with the plasma membrane, or they are released directly from the plasma membrane.

EVs are increasingly being recognized as important vehicles of communication between cells and as promising diagnostic and prognostic biomarkers in cancer. Despite the huge clinical potential, the wide variety of methods for separating EVs from biofluids, which provide material of highly variable purity, and the lack of knowledge regarding methodological reproducibility have impeded the entry of EVs into the clinical arena.

In an effort to increase the usefulness of EVs, investigators at Ghent University (Belgium) and colleagues at the University of Turku (Finland) used mass spectrometry-based proteomics to analyze EVs that had been separated and purified from urine by a novel procedure. This density-based fractionation of urine samples obtained from men with benign and malignant prostate disease by bottom-up Optiprep (the iodine-containing non-ionic radiocontrast agent iodixanol) density gradient centrifugation separated EVs and soluble proteins with high specificity and repeatability.

The investigators reported that differential quantitative proteomic analysis of EV-enriched and protein-enriched urine fractions identified unique and biologically and clinically relevant proteomes in urinary EVs. In addition, by profiling matched prostate cancer tissue-derived EVs and urinary EVs, they demonstrated that the urinary EV proteome was a reflection of that of EVs derived from the tissue of origin.

“Detecting and examining these vesicles in urine has an enormous potential for developing new tests for early detection of urological cancers. However, research related to this is still in its infancy,” said first author Bert Dhondt, a researcher in the laboratory for experimental cancer research at Ghent University. “In the future, the results of the study can aid patients with urological cancers through faster diagnosis and timely treatment.”

The proteomic analysis of EVs in the urine of prostate cancer patients was described in the March 11, 2020, online edition of Journal of Extracellular Vesicles.

Related Links:
Ghent University
University of Turku



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.